<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368378</url>
  </required_header>
  <id_info>
    <org_study_id>eDVCL</org_study_id>
    <nct_id>NCT03368378</nct_id>
  </id_info>
  <brief_title>Early DVC Ligation and Urinary Continence Recovery After RARP</brief_title>
  <official_title>Impact of Early Dorsal Venous Complex (eDVC) Ligation on Urinary Continence Recovery in Patients Undergoing Robot-assisted Radical Prostatectomy (RARP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the impact of early deep venous complex ligation (eDVCL)&#xD;
      in patients affected by clinically localized prostate cancer (PCa) undergoing robot-assisted&#xD;
      radical prostatectomy with or without pelvic lymph node dissection. Overall, 312 patients&#xD;
      will be randomized to the standard technique vs. eDVCL. The primary endpoint is represented&#xD;
      by early urinary continence recovery. The secondary endpoints are perioperative outcomes,&#xD;
      erectile function recovery and positive surgical margins.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early urinary continence recovery</measure>
    <time_frame>4 weeks</time_frame>
    <description>Continence recovery evaluated with the ICIQ-SF questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary continence recovery</measure>
    <time_frame>16 weeks</time_frame>
    <description>Continence recovery evaluated with Continence recovery evaluated with the ICIQ-SF questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile function recovery</measure>
    <time_frame>16 weeks</time_frame>
    <description>Erectile function recovery evaluated with the IIEF questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive surgical margins</measure>
    <time_frame>4 weeks</time_frame>
    <description>Positive surgical margins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA persistence or biochemical recurrence</measure>
    <time_frame>4, 16 and 48 weeks</time_frame>
    <description>Serum PSA levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative outcomes</measure>
    <time_frame>30 days</time_frame>
    <description>Postoperative complications according to the Clavien-Dindo classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During robot-assisted radical prostatectomy after the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The bladder neck will be then incised and preserved when possible. An inter-fascial or intra-fascial nerve-sparing technique will be then performed and the posterolateral aspect of the neurovascular bundles will be preserved. The DVC will be then isolated and selectively ligated using a V-lok 3/0 barbed suture. The anterolateral fibers of the neurovascular bundles will be then identified and preserved when possible. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Early DVC ligation</intervention_name>
    <description>After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male patients, aged between 18 and 80 years old&#xD;
&#xD;
          2. Planned to receive robot-assisted radical prostatectomy for prostate cancer&#xD;
&#xD;
          3. Able to understand and willing to sign a written informed consent document&#xD;
&#xD;
          4. On stable dose of current regular medication for at least 4 weeks prior to trial entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The participant may not enter the trial if ANY of the following apply:&#xD;
&#xD;
          1. Life expectancy of less than 12 months&#xD;
&#xD;
          2. Previous chemotherapy&#xD;
&#xD;
          3. Previous brachytherapy or external beam radiotherapy&#xD;
&#xD;
          4. Preexisting urinary incontinence defined as 1 or more pads per day&#xD;
&#xD;
          5. Unstable cardiovascular disease&#xD;
&#xD;
          6. Congestive Heart Failure (CHF)&#xD;
&#xD;
          7. Clinically significant hepatobiliary or renal disease&#xD;
&#xD;
          8. History of significant CNS injuries within 6 months&#xD;
&#xD;
          9. Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the participants at risk because of participation in the trial, or may&#xD;
             influence the result of the trial, or the participant's ability to participate in the&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Francesco Montorsi</investigator_full_name>
    <investigator_title>MD, FRCS (Hon), Professor and Chairman, Department of Urology Vita e Salute San Raffaele University, Milan, Italy</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>radical prostatectomy</keyword>
  <keyword>deep venous complex ligation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

